Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become
the malignant neoplasm of fastest growing incidence rate. More than 90% thyroid carcinoma is
thyroid differentiated carcinoma（DTC）. Postoperative oral L-thyroxine suppressing thyroid
stimulating hormone (TSH) treatment is the standard therapy in DTC patients. While
TSH-suppressive therapy with L-thyroxine can cause subclinical hyperthyroidism in treatment
of patients with thyroid differentiated carcinoma. The impact of this therapy on cognitive
functions and mood have not been systematically studied. The investigators infer the
subclinical hyperthyroidism caused by TSH-suppressive therapy may impact cognitive function
and mood disorders in DTC patients. The aim of this study is to explore the possible
mechanism of cognitive function impairment in the course of TSH-suppressive therapy by rat
model of total thyroidectomy + TSH-suppressive therapy and clinical trials. The result of
this study may provide clinical and experimental basis for the side effects risk result form
TSH-suppressive therapy in DTC patients.
Details
Lead Sponsor:
The Affiliated Hospital of Inner Mongolia Medical University